Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan

Lung Cancer

Volumn 65, Issue 1, 2009, Pages 91-97

  Nagata, Yoshika ^a   Hanagiri, Takeshi ^a   Mizukami, Makiko ^a   Kuroda, Koji ^a   Shigematsu, Yoshiki ^a   Baba, Tetsuro ^a   Ichiki, Yoshinobu ^a   Yasuda, Manabu ^a   So, Tomoko ^a   Takenoyama, Mitsuhiro ^a   Sugio, Kenji ^a   Nagashima, Akira ^b   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

Author keywords

HLA; Non small cell lung cancer (NSCLC); Prognosis; Surgical resection

Indexed keywords

HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA B52 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CYTOTOXICITY TEST; FEMALE; HISTOPATHOLOGY; HLA TYPING; HUMAN; HUMAN TISSUE; JAPAN; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PHENOTYPE; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SEROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HLA-B ANTIGENS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; YOUNG ADULT;

EID: 67349280890     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.10.012     Document Type: Article

References (53)

1. Goya T., Asamura H., Kato H., Shimokata K., Tsuchiya R., Yoshimura H., et al. The Japanese Joint Committee of Lung Cancer Registry, Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 50 (2005) 227-234
2. Asamura H., Goya T., Koshiishi Y., Eguchi K., Mori M., Sohara Y., et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol 3 (2008) 46-52
3. Kato H., Tsuboi M., Kato Y., Ikeda N., Okunaka T., and Hamada C. Postoperative adjuvant therapy for completely resected early-stage non-small cell lung cancer. Int J Clin Oncol 103 (2005) 157-164
4. Birim O., Kappetein A.P., van Klaveren R.J., and Bogers A.J. Prognostic factors in non-small cell lung cancer surgery. Eur J Surg Oncol 32 (2006) 12-23
5. Mountain C.F. The international system for staging lung cancer. Semin Surg Oncol 18 (2000) 106-115
6. Mandelboim O., Reyburn H.T., Pazmany L., Colonna M., Borsellino G., Vales-Gomez M., et al. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med 184 (1996) 913-922
7. Thorsby E., and Lie B.A. HLA associated genetic predisposition to autoimmune diseases: genes involved and possible mechanisms. Transpl Immunol 14 (2005) 175-182
8. Brewerton D.A., Hart F.D., Nicholls A., Caffrey M., James D.C., and Sturrock R.D. Ankylosing spondylitis and HL-A 27. Lancet 1 (1973) 904-907
9. Laroche C., Cremer G.A., Patri B., Remy J.M., and Letellier P. Association of Behcet's disease and pelvispondylitis in a subject without HLA W 27 antigen. Sem Hop 51 (1975) 2501-2508
10. Reinersten J.L., Klippel J.H., Johnson A.H., Steinberg A.D., Decker J.L., and Mann D.L. Family studies of B lymphocyte alloantigens in systemic lupus erythematosus. J Rheumatol 9 (1982) 253-262
11. Little A.M., and Stern P.L. Does HLA type predispose some individuals to cancer?. Mol Med Today 5 (1999) 337-342
12. Bateman A.C., and Howell W.M. Human leukocyte antigens and cancer: is it in our genes?. J Pathol 188 (1999) 231-236
13. Tang J., Shao W., Dorak M.T., Li Y., Miike R., Lobashevsky E., et al. Positive and negative associations of human leukocyte antigen variants with the onset and prognosis of adult glioblastoma multiforme. Cancer Epidemiol Biomarkers Prev. 14 (2005) 2040-2044
14. de Jong M.M., Niens M., Nolte I.M., te Meerman G.J., van der Graaf W.T., Mulder M.J., et al. The human leukocyte antigen region and colorectal cancer risk. Dis Colon Rectum 48 (2005) 303-306
15. Zoodsma M., Nolte I.M., Schipper M., Oosterom E., van der Steege G., de Vries E.G., et al. Analysis of the entire HLA region in susceptibility for cervical cancer: a comprehensive study. J Med Genet 42 (2005) e49
16. Dellon A.L., Rogentine Jr. G.N., and Chretien P.B. Prolonged survival in bronchogenic carcinoma associated with HL-A antigens W-19 and HL-A5: a preliminary report. J Natl Cancer Inst 54 (1975) 1283-1286
17. Rogentine Jr. C.N., Dellon A.L., and Chretien P.B. Prolonged disease-free survival in bronchogenic carcinoma associated with HLA-Aw19 and HLA-B5: a two-year prospective study. Cancer 39 (1977) 2345-2347
18. Weiss G.B., Nawrocki L.B., and Daniels J.C. HLA type and survival in lung cancer. Cancer 46 (1980) 38-40
19. Mottironi V.D., Banks S.M., Pollara B., and Rudofsky U.H. HLA and survival in lung cancer. Clin Immunol Immunopathol 45 (1987) 55-62
20. Tongio M.M., Kerschen C., Pauli G., Roeslin N., Grange D., and Mayer S. HLA antigens and primary bronchial carcinoma. Cancer 49 (1982) 2485-2488
21. Prazak J., Mericka O., and Chytry J. Histocompatibility locus antigens (HLA) in the epidermoid type of lung carcinoma. J Cancer Res Clin Oncol 116 (1990) 525-527
22. Ford C.H., Newman C.E., and Mackintosh P. HLA frequency and prognosis in lung cancer. Br J Cancer 43 (1981) 610-614
23. Ozbek N., Birinci A., Karaoglanoglu O., Coban A.Y., Okumus B., Cakir S., et al. HLA alleles and lung cancer in a Turkish population. Ann Saudi Med 24 (2004) 106-111
24. Tokumoto H. Analysis of HLA-DRB1-related alleles in Japanese patients with lung cancer--relationship to genetic susceptibility and resistance to lung cancer. J Cancer Res Clin Oncol 124 (1998) 511-516
25. So T., Takenoyama M., Sugaya M., Yasuda M., Eifuku R., Yoshimatsu T., et al. Unfavorable prognosis of patients with non-small cell lung carcinoma associated with HLA-A2. Lung Cancer 32 (2001) 39-46
26. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1710-1717
27. Terasaki P.I., and Mcclelland J.D. Microdroplet assay of human serum cytotoxins. Nature 204 (1964) 998-1000
28. Marsh S.G., Albert E.D., Bodmer W.F., Bontrop R.E., Dupont B., Erlich H.A., et al. Nomenclature for factors of the HLA system 2004. Tissue Antigens 65 (2005) 301-369
29. Hashimoto M., Kinoshita T., Yamasaki M., Tanaka H., Imanishi T., Ihara H., et al. Gene frequencies and haplotypic associations within the HLA region in 916 unrelated Japanese individuals. Tissue Antigens 44 (1994) 166-173
30. Terasaki P.I., Perdue S.T., and Mickey M.R. HLA frequencies in cancer: a second study. Genetics of human cancer (1977), Raven Press, New York pp. 321-8
31. Tokunaga K., Ishikawa Y., Ogawa A., Wang H., Mitsunaga S., Moriyama S., et al. Sequence-based association analysis of HLA class I and II alleles in Japanese supports conservation of common haplotypes. Immunogenetics 46 (1997) 199-205
32. Hughes A.L., and Nei M. Pattern of nucleotide substitution at major histocompatibility complex class I loci reveals overdominant selection. Nature 335 (1988) 167-170
33. Takahata N., Satta Y., and Klein J. Polymorphism and balancing selection at major histocompatibility complex loci. Genetics 130 (1992) 925-938
34. Robinson W.P., Cambon-Thomsen A., Borot N., Klitz W., and Thomson G. Selection, hitchhiking and disequilibrium analysis at three linked loci with application to HLA data. Genetics 129 (1991) 931-948
35. Carrington M., Nelson G.W., Martin M.P., Kissner T., Vlahov D., Goedert J.J., et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283 (1999) 1748-1752
36. Slatkin M. Balancing selection at closely linked, overdominant loci in a finite population. Genetics 154 (2000) 1367-1378
37. Shih C.M., Lee Y.L., Chiou H.L., Chen W., Chang G.C., Chou M.C., et al. Association of TNF-alpha polymorphism with susceptibility to and severity of non-small cell lung cancer. Lung Cancer 52 (2006) 15-20
38. Shimura T., Hagihara M., Takebe K., Munkhbat B., Odaka T., Kato H., et al. The study of tumor necrosis factor beta gene polymorphism in lung cancer patients. Cancer 73 (1994) 1184-1188
39. Zinkernagel R.M., and Doherty P.C. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature 251 (1974) 547-548
40. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 (1991) 1643-1647
41. Ichiki Y., Takenoyama M., Mizukami M., So T., Sugaya M., Yasuda M., et al. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol 172 (2004) 4844-4850
42. So T., Takenoyama M., Mizukami M., Ichiki Y., Sugaya M., Hanagiri T., et al. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res 65 (2005) 5945-5952
43. Nagata Y., Hanagiri T., Takenoyama M., Fukuyama T., Mizukami M., So T., et al. Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient. Clin Cancer Res 11 (2005) 5265-5272
44. Takenoyama M., Baurain J.F., Yasuda M., So T., Sugaya M., Hanagiri T., et al. A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma. Int J Cancer 118 (2006) 1992-1997
45. Fukuyama T., Hanagiri T., Takenoyama M., Ichiki Y., Mizukami M., So T., et al. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res 66 (2006) 4922-4928
46. Sugaya M., Takenoyama M., Shigematsu Y., Baba T., Fukuyama T., Nagata Y., et al. Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung. Int J Cancer 120 (2007) 1055-1062
47. Guéguen M., Patard J.J., Gaugler B., Brasseur F., Renauld J.C., Van Cangh P.J., et al. An antigen recognized by autologous CTLs on a human bladder carcinoma. J Immunol 160 (1998) 6188-6194
48. Jaramillo A., Narayanan K., Campbell L.G., Benshoff N.D., Lybarger L., Hansen T.H., et al. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Breast Cancer Res Treat 88 (2004) 29-41
49. Marincola F.M., Shamamian P., Alexander R.B., Gnarra J.R., Turetskaya R.L., Nedospasov S.A., et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 153 (1994) 1225-1237
50. Baba T., Hanagiri T., Ichiki Y., Kuroda K., Shigematsu Y., Mizukami M., et al. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B. Cancer Sci 98 (2007) 1795-1802
51. Ramnath N., Tan D., Li Q., Hylander B.L., Bogner P., Ryes L., et al. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival?. Immunotherapy 55 (2006) 891-899
52. Wang Z., Marincola F.M., Rivoltini L., Parmiani G., and Ferrone S. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med 190 (1999) 205-215
53. Kageshita T., Kawakami Y., and Ono T. Clinical significance of MART-1 and HLA-A2 expression and CD8 + T cell infiltration in melanocytic lesions in HLA-A2 phenotype patients. J Dermatol Sci 25 (2001) 36-44